PD-L1 expression in melanoma: A quantitative immunohistochemical antibody comparison

Clinical Cancer Research

Volumn 23, Issue 16, 2017, Pages 4938-4944

  Sunshine, Joel C ^a   Nguyen, Peter L ^a   Kaunitz, Genevieve J ^a   Cottrell, Tricia R ^b   Berry, Sneha ^a   Esandrio, Jessica ^a   Xu, Haiying ^a   Ogurtsova, Aleksandra ^a   Bleich, Karen B ^a   Cornish, Toby C ^b   Lipson, Evan J ^a   Anders, Robert A ^b   Taube, Janis M ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSTITUTIONAL REVIEW; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TUMOR MICROENVIRONMENT; BIOSYNTHESIS; COMPARATIVE STUDY; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; PATHOLOGY, CLINICAL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 85028074698     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1821     Document Type: Article

References (23)

1. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4: 127ra37.
2. Tumeh P, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–71.
3. Topalian ST, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020–30.
4. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320–30.
5. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti- CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375–84.
6. Topalian ST, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
7. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064–74.
8. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563–7.
9. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol 2015;42:587–600.
10. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015;23:32–8.
11. Taube JM. Unleashing the immune system: PD-1 and PD-Ls in the pretreatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. Oncoimmunology 2014;3:e96341.
12. Hansen AR, Siu LL. PD-L1 testing in cancer: challenges in companion diagnostic development. JAMA Oncol 2016;2:15–6.
13. Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res 2015;21:3969–76.
14. Rodic N, Anders RA, Eshleman JR, Lin MT, Xu H, Kim JH, et al. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. Cancer Immunol Res 2015;3:110–5.
15. Zarrella ER, Coulter M, Welsh AW, Carvajal DE, Schalper KA, Harigopal M, et al. Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurement. Lab Invest 2016;96:1016–25.
16. Mahoney KM, Sun H, Liao X, Hua P, Callea M, Greenfield EA, et al. PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells. Cancer Immunol Res 2015;3:1308–15.
17. Garber K. Predictive biomarkers for checkpoints, first tests approved. Nat Biotechnol 2015;33:1217–8.
18. Gaule P, Smithy JW, Toki M, Rehman J, Patell-Socha F, Cougot D, et al. A quantitative comparison of antibodies to programmed cell death 1 ligand 1. JAMA Oncol. 2016 Aug 18. [Epub ahead of print].
19. Topalian ST, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016;16:275–87.
20. Hirsh FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kalangara K, et al. PD-L1 assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. Session: The Blueprint Project: Comparing PD-L1 IHC Diagnostics for Immune Checkpoint Inhibitors. J Thorac Oncol 2017;12:208–22.
21. Rimm D, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, et al. ORAL01.01: a prospective, multi-institutional assessment of four assays for PD-L1 expression in NSCLC by immunohistochemistry: topic: pathology. J Thorac Oncol 2016;11:S249.
22. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small cell lung cancer. JAMA Oncol 2016;2:46–54.
23. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.